Steroids, NSAIDs, anti-allergy drugs and immunosuppression
Inflammation damages the eye faster than almost any other tissue, because the eye depends on being clear. Corticosteroids are the most powerful drugs for suppressing it and also the most dangerous, and every student should be able to list their ocular complications without hesitating. This lesson covers steroids by every route, the non-steroidal drops, the drugs for allergic eye disease, ciclosporin, and an outline of the systemic immunosuppressants and biologics used when steroids are not enough.
How steroids work and how they are given
Corticosteroids enter cells, bind the glucocorticoid receptor and change which genes are switched on. The net effect is a broad shutdown of inflammation. One important step is inhibition of phospholipase A2, the enzyme that releases arachidonic acid from cell membranes. Without arachidonic acid the cell cannot make prostaglandins or leukotrienes. Steroids also reduce the migration of white cells, stabilise leaky blood vessels and suppress scarring and new vessel growth. They suppress inflammation whatever its cause. That is their strength, and it is also why they are harmful in untreated infection.
The route is chosen by the site of the inflammation, following the rule from the first lesson of this chapter that drops reach the front of the eye and not the back.
| Route | Preparation | Typical use |
|---|---|---|
| Topical | Prednisolone, dexamethasone, fluorometholone, loteprednol drops | Anterior uveitis, after surgery, corneal graft rejection, severe allergic eye disease |
| Periocular (sub-Tenon or orbital floor) | Depot triamcinolone | Intermediate or posterior uveitis and macular oedema, usually one eye |
| Intravitreal | Dexamethasone implant, fluocinolone implant, triamcinolone | Macular oedema from vein occlusion, diabetes or uveitis; non-infectious posterior uveitis |
| Systemic | Oral prednisolone, intravenous methylprednisolone | Giant cell arteritis, scleritis, sight-threatening posterior uveitis, optic neuritis |
Topical steroids differ in strength and in how well they enter the eye. Prednisolone acetate 1% and dexamethasone 0.1% are the strong ones, used for inflammation inside the eye. Fluorometholone and loteprednol are weaker or are broken down quickly inside the eye, so they are used for surface inflammation and raise pressure less. The BNF advises that topical steroids are applied frequently for the first 24 to 48 hours, for prednisolone every 1 to 2 hours, and then reduced as the inflammation comes under control. They are tapered, not stopped abruptly, because inflammation rebounds.
The dangers of steroids in the eye
The BNF states that topical steroids should normally be used only under expert supervision and names three main dangers.
- Infection made worse. A red eye of unconfirmed cause may be herpes simplex keratitis. A steroid lets the virus spread, and can lead to corneal ulceration and loss of the eye. Bacterial, fungal and amoebic infections carry a similar hazard.
- Steroid glaucoma. Pressure rises in susceptible people.
- Steroid cataract. This follows prolonged use, and the risk rises with dose and duration.
The steroid response is a rise in intraocular pressure caused by steroid treatment. Steroids act on the cells of the trabecular meshwork. The cells lay down more extracellular material, their internal skeleton stiffens and they clear debris less well, so resistance to aqueous outflow goes up. With drops the rise usually appears 3 to 6 weeks after starting and settles within a few weeks of stopping, though after long courses it may persist. People who make this response are called steroid responders. It is more likely in patients with primary open-angle glaucoma, their first-degree relatives, people with high myopia or diabetes, young children and anyone who has responded before.
The size of the rise tracks the potency and the route. In one study of known responders, quoted by EyeWiki, the average rise was about 6 mmHg with fluorometholone 0.1%, 10 mmHg with prednisolone 1% and 22 mmHg with dexamethasone 0.1%. Injected steroid is riskier than drops, and intravitreal steroid is riskiest of all. Steroid by any route can do it, including tablets and injections into joints. The evidence for inhaled and nasal steroid is mixed.
The steroid cataract is typically a posterior subcapsular cataract: an opacity at the back of the lens, on the visual axis, which causes glare and poor reading vision out of proportion to its size. Other problems include delayed wound healing and thinning of an already damaged cornea.
Periocular and intravitreal steroid
When the target is the retina, steroid has to be delivered behind the lens. A depot of triamcinolone placed under Tenon's capsule or on the orbital floor soaks through the sclera over weeks. For a stronger and more sustained effect, steroid is put into the vitreous.
- The dexamethasone implant (Ozurdex) is a biodegradable rod injected through the pars plana. The BNF lists it for macular oedema after branch or central retinal vein occlusion, diabetic macular oedema and non-infectious posterior segment uveitis.
- The fluocinolone acetonide implant (Iluvien) releases a low dose for much longer. It is licensed for chronic diabetic macular oedema that has responded insufficiently to other treatment, and to prevent relapse of recurrent non-infectious posterior uveitis.
The two predictable costs are cataract and raised pressure. In the main diabetic macular oedema trial of the dexamethasone implant about one-third of patients had a clinically significant pressure rise, although very few needed glaucoma surgery. The BNF contraindicates the dexamethasone implant in active or suspected ocular infection and in uncontrolled advanced glaucoma. It also warns that where the posterior lens capsule is torn or the iris is defective the implant can migrate into the anterior chamber and damage the cornea.
Non-steroidal anti-inflammatory drops
NSAIDs block cyclo-oxygenase, the enzyme that converts arachidonic acid into prostaglandins. They act one step further down the same pathway as steroids and block only one branch of it, so they are weaker but avoid the steroid complications: they do not raise pressure or cause cataract. The topical drugs are ketorolac, nepafenac, bromfenac and diclofenac. Nepafenac is a prodrug converted to its active form inside the eye.
Their uses follow from what prostaglandins do in the eye, which is to cause pain, leaky vessels and pupil constriction during surgery. The BNF lists them for the prevention and treatment of inflammation after eye surgery or laser. Nepafenac is also licensed to reduce the risk of macular oedema after cataract surgery in people with diabetes, and diclofenac is licensed for seasonal allergic conjunctivitis.
The serious adverse effect is on the cornea. Prolonged use can cause epithelial breakdown, corneal thinning, ulceration and perforation, known as a corneal melt. The BNF advises stopping immediately if there is evidence of epithelial breakdown. NSAID drops also sting, may slow wound healing and increase the tendency of ocular tissues to bleed.
Drugs for allergic eye disease
Seasonal allergic conjunctivitis is a type I hypersensitivity reaction. Allergen cross-links IgE on conjunctival mast cells, the cells release histamine, and histamine causes itching, redness and watering. Two drug groups interrupt this at different points.
| Mast cell stabilisers | Topical antihistamines | |
|---|---|---|
| Examples | Sodium cromoglicate, nedocromil, lodoxamide | Azelastine, epinastine, antazoline |
| Action | Stop mast cells releasing their contents | Block histamine H1 receptors |
| Speed | Slow; preventive | Fast relief of itch |
| How used | Regularly through the season; cromoglicate four times daily | When symptoms occur or regularly |
| Good for | Predictable seasonal symptoms, vernal keratoconjunctivitis | Acute symptoms |
A mast cell stabiliser does nothing to histamine that has already been released, so it must be started before exposure and used regularly. An antihistamine works within minutes but does not stop the release. Olopatadine and ketotifen do both jobs in one drop and are used twice daily. Antazoline is sold combined with xylometazoline, a vasoconstrictor that whitens the eye.
Chronic allergic disease that threatens the cornea, such as vernal and atopic keratoconjunctivitis, may need short courses of topical steroid under specialist supervision, or topical ciclosporin to avoid steroid.
Ciclosporin, immunosuppressants and biologics
Ciclosporin is a calcineurin inhibitor. Blocking calcineurin stops T cells producing interleukin-2 and other lymphokines, so the cell-mediated immune response is suppressed. As an eye drop it reduces surface inflammation without the pressure rise or cataract of a steroid. In the UK the BNF lists ciclosporin drops, started by a specialist, for severe keratitis in dry eye disease that has not improved with tear substitutes. The drops sting, and active or suspected eye infection is a contraindication.
Long-term systemic steroid causes diabetes, osteoporosis, weight gain, hypertension and infection. When sight-threatening inflammation needs months or years of treatment, a second drug is added so that the steroid dose can be brought down. This is a steroid-sparing agent. The detail belongs to the uveitis chapter; the groups to recognise are these:
- Antimetabolites: methotrexate, mycophenolate mofetil and azathioprine. They slow the division of lymphocytes. All can suppress the bone marrow and upset the liver, so blood tests are monitored.
- Calcineurin inhibitors: ciclosporin and tacrolimus by mouth. Kidney damage and hypertension are the main concerns.
- Alkylating agents: cyclophosphamide, kept for the most severe disease such as necrotising scleritis with systemic vasculitis.
- Biologics: antibodies against a single target. Adalimumab binds tumour necrosis factor alpha and is recommended by NICE, with a dexamethasone implant as the other option, for non-infectious uveitis. Infliximab is another anti-TNF antibody. Rituximab depletes B cells, and tocilizumab blocks the interleukin-6 receptor.
Anti-TNF drugs carry particular warnings. The BNF notes serious infections including reactivation of tuberculosis and hepatitis B, so patients are screened first. They can also worsen demyelinating disease, and the manufacturer advises assessing patients with uveitis for demyelinating disorders before and during treatment. This matters because intermediate uveitis is itself associated with multiple sclerosis.
Summary
- Steroids inhibit phospholipase A2 and many other inflammatory pathways; NSAIDs inhibit cyclo-oxygenase only.
- The three BNF dangers of topical steroid are worsening of herpetic and other infection, steroid glaucoma and steroid cataract.
- The steroid response is a pressure rise from increased resistance in the trabecular meshwork, typically 3 to 6 weeks after starting drops.
- Dexamethasone and prednisolone raise pressure more than fluorometholone or loteprednol, and intravitreal steroid more than drops.
- The steroid cataract is posterior subcapsular.
- Dexamethasone and fluocinolone implants treat macular oedema and non-infectious posterior uveitis at the cost of cataract and raised pressure.
- Topical NSAIDs do not raise pressure but can cause corneal melt, especially with steroid drops.
- Mast cell stabilisers prevent histamine release and work slowly; antihistamines give rapid relief; olopatadine and ketotifen do both.
- Ciclosporin is a calcineurin inhibitor that suppresses T cells and is used topically for severe dry eye keratitis.
- Adalimumab is an anti-TNF antibody used for non-infectious uveitis; tuberculosis and demyelination must be considered.
Check yourself
Quick recall on this lesson. These are easier than the question bank.
Written for revision. It is not a source of clinical advice, and guidance changes.